Female Hormone Optimization

0.5-100% lower risk of developing disease

3.5-97% reduction in symptoms

Increases by 45-64.2 g/dL

Increases by 4.2-14.2 hemoglobin for anemia

10% lower relative risk

1.9-65.2% reduction in symptoms for depression

0.6-10% reduction in symptoms

Increases by 3.6-8.5 MPa

Increases by 2-81 days hospitalized for depression

351% higher relative risk

10.6% reduction in symptoms for anxiety

Increases by 10.6 points on SAS scale for anxiety

32.1-93.3% reduction in symptoms

Increases by 24-40 mm

Decreases blood level by 9.4-7.9 mg/dL for type 2 diabetes. Change in blood concentration of the measured substance.

Improves blood pressure by 18.7-24 mmHg for hypertension. Lower blood pressure reduces risk of heart attack, stroke, and kidney disease.

Increases by 9.4-8.3 log2 units for cardiovascular disease

60% reduction in symptoms for premenstrual syndrome

1.2-6.4% reduction in symptoms

Increases by 6.4-12.2 Higham mean score difference

Increases by 4.1 μIU/mL for polycystic ovary syndrome

33% lower relative risk

32.1-90% reduction in symptoms

Large measurable increase (effect size: 2.2). Effects above 0.8 are considered large, 0.5 moderate, 0.2 small.

Minimal measurable increase for obesity (effect size: 0.1). Effects above 0.8 are considered large, 0.5 moderate, 0.2 small.

Decreases percentage change by 11.5-12.4 percent for type 2 diabetes. Percentage improvement in the measured outcome.

32% lower relative risk

Improves body weight by 5.5-7.9 kg. Weight change from the intervention.

Reduces by 3.1-3.9 ratio for polycystic ovary syndrome

Improves blood level by 2.6-12.6 nmol/L for PCOS. Change in blood concentration.

Large measurable improvement for type 2 diabetes (effect size: 3.5). Effects above 0.8 are considered large, 0.5 moderate, 0.2 small.

24% higher relative risk

1.9-71% reduction in symptoms

5-91.5% reduction in symptoms for depression

Improves percentage change by 12.5-30 percent. Percentage improvement in the measured outcome.

Large measurable increase for cardiovascular disease (effect size: 4.0). Effects above 0.8 are considered large, 0.5 moderate, 0.2 small.

Small measurable increase for cancer (effect size: 0.4). Effects above 0.8 are considered large, 0.5 moderate, 0.2 small.